TY - JOUR
T1 - Diversity in modern heart failure trials
T2 - Where are we, and where are we going
AU - Anaba, Uzoma
AU - Ishola, Abiodun
AU - Alabre, Alisha
AU - Bui, Albert
AU - Prince, Marloe
AU - Okafor, Henry
AU - Kola-Kehinde, Onaopepo
AU - Joseph, Joshua J.
AU - Mitchell, Darrion
AU - Odei, Bismarck C.
AU - Uzendu, Anezi
AU - Williams, Karen Patricia
AU - Capers, Quinn
AU - Addison, Daniel
N1 - Funding Information:
Dr. Uzendu is currently supported by the National Heart, Lung and Blood Institutes of Health under Award Number 5T32H110837 . The content is solely the responsibility of the author(s) and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
This work was supported in part by NIH grants K12-CA133250 (DA), K23-HL155890 (DA), K23-DK117041 (JJJ), P30 CA016058 , and The Robert Wood Johnson Foundation ( Harold Amos Medical Faculty Development Program ID# 76236 (JJJ) and The Robert Wood Johnson Foundation (Harold Amos Medical Faculty Development Program)- American Heart Association Faculty Development Program grant (DA).
Publisher Copyright:
© 2021
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Over the last three decades, increased attention has been given to the representation of historically underrepresented groups within the landscape of pivotal clinical trials. However, recent events (i.e., coronavirus pandemic) have laid bare the potential continuation of historic inequities in available clinical trials and studies aimed at the care of broad patient populations. Anecdotally, cardiovascular disease (CVD) has not been immune to these disparities. Within this review, we examine and discuss recent landmark CVD trials, with a specific focus on the representation of Blacks within several critically foundational heart failure clinical trials tied to contemporary treatment strategies and drug approvals. We also discuss solutions for inequities within the landscape of cardiovascular trials. Building a more diverse clinical trial workforce coupled with intentional efforts to increase clinical trial diversity will advance equity in cardiovascular care.
AB - Over the last three decades, increased attention has been given to the representation of historically underrepresented groups within the landscape of pivotal clinical trials. However, recent events (i.e., coronavirus pandemic) have laid bare the potential continuation of historic inequities in available clinical trials and studies aimed at the care of broad patient populations. Anecdotally, cardiovascular disease (CVD) has not been immune to these disparities. Within this review, we examine and discuss recent landmark CVD trials, with a specific focus on the representation of Blacks within several critically foundational heart failure clinical trials tied to contemporary treatment strategies and drug approvals. We also discuss solutions for inequities within the landscape of cardiovascular trials. Building a more diverse clinical trial workforce coupled with intentional efforts to increase clinical trial diversity will advance equity in cardiovascular care.
KW - Black
KW - Cardiovascular clinical trials
KW - Disparities
UR - http://www.scopus.com/inward/record.url?scp=85121767980&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121767980&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2021.12.018
DO - 10.1016/j.ijcard.2021.12.018
M3 - Article
C2 - 34920047
AN - SCOPUS:85121767980
SN - 0167-5273
VL - 348
SP - 95
EP - 101
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -